Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation With OFDI of Strut Coverage of Terumo New Drug Eluting Stent (Development Code TCD-10023) With Biodegradable Polymer at 1, 2 and 3 Months

Trial Profile

Evaluation With OFDI of Strut Coverage of Terumo New Drug Eluting Stent (Development Code TCD-10023) With Biodegradable Polymer at 1, 2 and 3 Months

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2018

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Coronary artery disease; Myocardial infarction; Thrombosis; Venous thromboembolism
  • Focus Registrational; Therapeutic Use
  • Acronyms DISCOVERY123
  • Sponsors Terumo
  • Most Recent Events

    • 03 Jul 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2016.
    • 03 Jul 2016 Planned primary completion date changed from 1 Jun 2015 to 1 Sep 2016.
    • 11 May 2015 Planned End Date changed from 1 Jan 2016 to 1 Mar 2016, according to to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top